MD Anderson at ESMO
Each year, oncology professionals around the globe convene for The European Society for Medical Oncology Congress. MD Anderson's experts present the latest advances in cancer care and lead the discussion of its application in the clinic to benefit patients. From promising discoveries in Phase I clinical trials to expanding and improving immunotherapies, our research is saving lives and preserving patients' quality of life.
Below is a snapshot of the work our experts are presenting virtually at The European Society for Medical Oncology Virtual Congress 2020 as well as more on our pacesetting patient care.
Featured Articles
KRAS inhibitor sotorasib appears safe, achieves durable clinical benefit in early trial
Phase I study encouraging for patients with advanced cancers and KRAS G12C mutations
Progress in treating medullary thyroid cancer
Medullary thyroid cancer is rare, but a large number of cases are linked to the RET gene mutation. New targeted therapies called RET inhibitors are offering some patients a better treatment option with fewer side effects. Mimi Hu, M.D., shares the latest clinical trial results and what’s ahead with research.
BRAF inhibitors and other targeted therapies, as well as a combination of chemotherapy and immunotherapy, are among the new treatments being tested through Phase I clinical trials. Learn about results shared by MD Anderson experts at ESMO Virtual Congress 2020.
Moon Shots Program
MD Anderson's Moon Shots® Program aims to rapidly and dramatically improve the disease's survival rates and reduce suffering through early detection, research and new treatments.
Learn more about the Moon Shots ProgramMD Anderson News
Find out more about the MD Anderson departments presenting at ESMO 2020.
Tap into MD Anderson's expertise with these tools and resources for your clinic.
Education and Training
Explore our comprehensive educational programs that are preparing the next generation to join the fight to end cancer.